{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T10:50:20Z","timestamp":1786531820387,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,3]]},"DOI":"10.7759\/cureus.39903","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T13:15:25Z","timestamp":1685798125000},"source":"Crossref","is-referenced-by-count":7,"title":["Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD): A Systematic Review"],"prefix":"10.7759","author":[{"given":"Alex S","family":"Aguirre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga  M","family":"Astudillo Moncayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Mosquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica E","family":"Muyolema Arce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Gallegos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Fernando","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres F","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"O\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja J","family":"Buj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"The epidemiology of neuromuscular disorders: a comprehensive overview of the literature","volume":"2","author":"Deenen JC","year":"2015","unstructured":"Deenen JC, Horlings CG, Verschuuren JJ, et al.. The epidemiology of neuromuscular disorders: a comprehensive overview of the literature. J Neuromuscul Dis. 2015, 2:73-85.","journal-title":"J Neuromuscul Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001783","article-title":"Evidence-based guideline summary: evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine","volume":"85","author":"Tawil R","year":"2015","unstructured":"Tawil R, Kissel JT, Heatwole C, et al.. Evidence-based guideline summary: evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology. 2015, 85:357-364. 10.1212\/WNL.0000000000001783","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-00675-3","article-title":"Facioscapulohumeral muscular dystrophy: update on pathogenesis and future treatments","volume":"15","author":"Hamel J","year":"2018","unstructured":"Hamel J, Tawil R. Facioscapulohumeral muscular dystrophy: update on pathogenesis and future treatments. Neurotherapeutics. 2018, 15:863-871. 10.1007\/s13311-018-00675-3","journal-title":"Neurotherapeutics"},{"key":"ref4","article-title":"Facioscapulohumeral Muscular Dystrophy","author":"Fecek C","year":"2023","unstructured":"Fecek C, Emmady PD. Facioscapulohumeral Muscular Dystrophy. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2015-001353","article-title":"What's in a name? The clinical features of facioscapulohumeral muscular dystrophy","volume":"16","author":"Mul K","year":"2016","unstructured":"Mul K, Lassche S, Voermans NC, et al.. What's in a name? The clinical features of facioscapulohumeral muscular dystrophy. Pract Neurol. 2016, 16:201-207. 10.1136\/practneurol-2015-001353","journal-title":"Pract Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2010.04.007","article-title":"171st ENMC international workshop: standards of care and management of facioscapulohumeral muscular dystrophy","volume":"20","author":"Tawil R","year":"2010","unstructured":"Tawil R, van der Maarel S, Padberg GW, et al.. 171st ENMC international workshop: standards of care and management of facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 2010, 20:471-475. 10.1016\/j.nmd.2010.04.007","journal-title":"Neuromuscul Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher D","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al.. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009, 6:e1000097. 10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2008.12.027","article-title":"Periodic salbutamol in facioscapulohumeral muscular dystrophy: a randomized controlled trial","volume":"90","author":"Payan CA","year":"2009","unstructured":"Payan CA, Hogrel JY, Hammouda EH, et al.. Periodic salbutamol in facioscapulohumeral muscular dystrophy: a randomized controlled trial. Arch Phys Med Rehabil. 2009, 90:1094-1101. 10.1016\/j.apmr.2008.12.027","journal-title":"Arch Phys Med Rehabil"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000134660.30793.1f","article-title":"Strength training and albuterol in facioscapulohumeral muscular dystrophy","volume":"63","author":"van der Kooi EL","year":"2004","unstructured":"van der Kooi EL, Vogels OJ, van Asseldonk RJ, et al.. Strength training and albuterol in facioscapulohumeral muscular dystrophy. Neurology. 2004, 63:702-708. 10.1212\/01.wnl.0000134660.30793.1f","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.50.5.1402","article-title":"Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group","volume":"50","author":"Kissel JT","year":"1998","unstructured":"Kissel JT, McDermott MP, Natarajan R, et al.. Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group. Neurology. 1998, 50:1402-1406. 10.1212\/wnl.50.5.1402","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.57.8.1434","article-title":"Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy","volume":"57","author":"Kissel JT","year":"2001","unstructured":"Kissel JT, McDermott MP, Mendell JR, et al.. Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology. 2001, 57:1434-1440. 10.1212\/wnl.57.8.1434","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14884","article-title":"Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement","volume":"87","author":"Mellion ML","year":"2021","unstructured":"Mellion ML, Ronco L, Berends CL, et al.. Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement. Br J Clin Pharmacol. 2021, 87:4658-4669. 10.1111\/bcp.14884","journal-title":"Br J Clin Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000264017.08217.39","article-title":"Pilot trial of diltiazem in facioscapulohumeral muscular dystrophy","volume":"68","author":"Elsheikh BH","year":"2007","unstructured":"Elsheikh BH, Bollman E, Peruggia M, et al.. Pilot trial of diltiazem in facioscapulohumeral muscular dystrophy. Neurology. 2007, 68:1428-1429. 10.1212\/01.wnl.0000264017.08217.39","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2014.09.014","article-title":"Effects of vitamin C, vitamin E, zinc gluconate, and selenomethionine supplementation on muscle function and oxidative stress biomarkers in patients with facioscapulohumeral dystrophy: a double-blind randomized controlled clinical trial","volume":"81","author":"Passerieux E","year":"2015","unstructured":"Passerieux E, Hayot M, Jaussent A, et al.. Effects of vitamin C, vitamin E, zinc gluconate, and selenomethionine supplementation on muscle function and oxidative stress biomarkers in patients with facioscapulohumeral dystrophy: a double-blind randomized controlled clinical trial. Free Radic Biol Med. 2015, 81:158-169. 10.1016\/j.freeradbiomed.2014.09.014","journal-title":"Free Radic Biol Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27558","article-title":"Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy","volume":"66","author":"Statland JM","year":"2022","unstructured":"Statland JM, Campbell C, Desai U, et al.. Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy. Muscle Nerve. 2022, 66:50-62. 10.1002\/mus.27558","journal-title":"Muscle Nerve"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21338","article-title":"A phase I\/II trial of MYO-029 in adult subjects with muscular dystrophy","volume":"63","author":"Wagner KR","year":"2008","unstructured":"Wagner KR, Fleckenstein JL, Amato AA, et al.. A phase I\/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008, 63:561-571. 10.1002\/ana.21338","journal-title":"Ann Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/729598","article-title":"Muscle plasticity and \u03b2\u2082-adrenergic receptors: adaptive responses of \u03b2\u2082-adrenergic receptor expression to muscle hypertrophy and atrophy","volume":"2011","author":"Sato S","year":"2011","unstructured":"Sato S, Shirato K, Tachiyashiki K, et al.. Muscle plasticity and \u03b2\u2082-adrenergic receptors: adaptive responses of \u03b2\u2082-adrenergic receptor expression to muscle hypertrophy and atrophy. J Biomed Biotechnol. 2011, 2011:729598. 10.1155\/2011\/729598","journal-title":"J Biomed Biotechnol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1042\/bj2610001","article-title":"Multiple actions of beta-adrenergic agonists on skeletal muscle and adipose tissue","volume":"261","author":"Yang YT","year":"1989","unstructured":"Yang YT, McElligott MA. Multiple actions of beta-adrenergic agonists on skeletal muscle and adipose tissue. Biochem J. 1989, 261:1-10. 10.1042\/bj2610001","journal-title":"Biochem J"},{"key":"ref20","unstructured":"Kinoshita J. ReDUX4 trial result exceeds expectations. FSHD Soc. (2021). Accessed: November 19, 2022: https:\/\/www.fshdsociety.org\/2021\/06\/24\/redux4-trial-result-exceeds-expectations\/."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2005.04.035","article-title":"Fascioscapulohumeral muscular dystrophy: a progressive degenerative disease that responds to diltiazem","volume":"65","author":"Lefkowitz DL","year":"2005","unstructured":"Lefkowitz DL, Lefkowitz SS. Fascioscapulohumeral muscular dystrophy: a progressive degenerative disease that responds to diltiazem. Med Hypotheses. 2005, 65:716-721. 10.1016\/j.mehy.2005.04.035","journal-title":"Med Hypotheses"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/122170-treatment-of-facioscapulohumeral-muscular-dystrophy-fshd-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:04:42Z","timestamp":1707509082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/122170-treatment-of-facioscapulohumeral-muscular-dystrophy-fshd-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,3]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.39903","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,3]]}}}